Lonafarnib is a potential inhibitor for neovascularization.

Sun L, Xie S, Peng G, Wang J, Li Y, Qin J, Zhong D

DOI: 10.1371/journal.pone.0122830
Published: 2015
Container: PloS one
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0122830,
  title = {Lonafarnib is a potential inhibitor for neovascularization.},
  author = {Sun L and Xie S and Peng G and Wang J and Li Y and Qin J and Zhong D},
  year = {2015},
  journal = {PloS one},
  doi = {10.1371/journal.pone.0122830},
  url = {https://doi.org/10.1371/journal.pone.0122830}
}

RIS

TY  - JOUR
TI  - Lonafarnib is a potential inhibitor for neovascularization.
AU  - Sun L
AU  - Xie S
AU  - Peng G
AU  - Wang J
AU  - Li Y
AU  - Qin J
AU  - Zhong D
PY  - 2015
JO  - PloS one
DO  - 10.1371/journal.pone.0122830
UR  - https://doi.org/10.1371/journal.pone.0122830
ER  -

APA

L, S., S, X., G, P., J, W., Y, L., J, Q., & D, Z. (2015). Lonafarnib is a potential inhibitor for neovascularization.. PloS one. https://doi.org/10.1371/journal.pone.0122830

Source records

pubmed · retrieved 2026-09-25T17:53:46.401Z